Recently, Taiyuan Health Commission issued a comprehensive reshuffle of local primary medical institutions. The key contents of this document are as follows: it is strictly forbidden for the staff in the health center to be seconded to the higher level, the village doctors who fail to meet the standards will stop practicing, the village doctors will be evaluated and managed by the village, the village clinics will be secretly visited, and the village doctors will be granted the qualification of practicing doctors plus subsidies.
recently, Johnson & Johnson amivanatamab and lazertinib have been approved for two clinical trials in China. They are: 1) combination therapy for EGFR exon 19 deletion or L858R activation mutation in patients with locally advanced or progressive NSCLC without previous treatment; 2) combination therapy for EGFR NSCLC patients with deletion of exon 19 or L858R activation mutation and disease progression after first-line treatment with first-generation or second-generation TKI or first-line or second-line treatment with third-generation TKI.
Novartis said in a statement on the 23rd that it had recently received feedback from the US FDA that it could not accept the application for phase 1 / 2 clinical trial data based on intravenous injection forms, and suggested that avxs-101 it dosage form conduct a key phase 3 confirmatory study to supplement the existing strong data and further support regulatory submission. Zolgensma IV, previously approved by FDA, can be used in children under 2 years old. Novartis hopes that the new it injection can extend the indications to children under 5 years old and complete the application for marketing in 2021. However, the latest FDA recommendation will delay the application to 2023 at least.
Pfizer recently announced that the US FDA has accepted a supplementary drug application for xalkori, a targeted anticancer drug, and granted priority review. The SNDA seeks to approve xalkori as a new indication for the treatment of anaplastic lymphoma kinase positive, recurrent or refractory systemic anaplastic large cell lymphoma in pediatric patients.
on the 23rd, sun pharmaceutical of India said that it would recall some batches of riomet Er, a sustained-release version of the diabetes drug riomet. The reason for the recall is that the potential content of nitrosamine impurity N-nitrosodimethylamine exceeds the daily intake permitted by FDA.
from 0:00 to 24:00 on September 23, 7 new confirmed cases were reported in 31 provinces and Xinjiang production and Construction Corps, all of which were imported cases from abroad; there were no new death cases and no new suspected cases. Pigtail is the most delicious way to do, super simple, women often eat, beauty and beauty, delay aging